NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading XRAY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround play, as XRAY is currently loss-making but has a stable management team focused on executing a return-to-growth plan. The current thesis state is mixed, with some positive sector momentum but limited progress in financial performance.
The market seems to have priced in a low expectations gap, suggesting that XRAY is viewed as cheap compared to its peers. However, the valuation reflects a justified stance given the company's ongoing losses and mixed recent performance.
Fundamentals are likely to remain neutral in the near term, as management's execution of their growth plan has shown limited progress. The company reported a slight revenue increase year-over-year but continues to face challenges, including a net loss in the most recent quarter.
The thesis hinges on several factors, including the performance of sector bellwethers like ISRG, MDLN, and BDX, which could influence XRAY's trajectory. Additionally, any changes in guidance from management could significantly impact investor sentiment.
Over the next 1 to 3 years, XRAY's performance will depend on its ability to execute its growth strategies and navigate sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if the company is improving or facing more challenges.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue growth below 0% year over year.
Why it matters: Adjusted EPS is an important measure of profit. Meeting or beating the guidance shows good cost management.
Confirms:Adjusted EPS for Q1 2026 is over $0.27. This means better-than-expected profit.
Disproves:Adjusted EPS for Q1 2026 is below $0.27. This suggests ongoing profit issues.
Why it matters: Keeping the dividend shows care for shareholders, even in hard times.
Confirms one read:The company keeps its quarterly dividend at $0.16 per share this quarter.
Confirms the other:The company cuts or stops the quarterly dividend payment.
Why it matters: Better operating income shows progress in managing costs. This is very important.
Confirms:Q2 operating income improves to above -$20M. This means better cost management.
Disproves:Q2 operating income stays below -$35M. This shows ongoing issues with cost management.
Why it matters: A drop below median growth could signal a broader issue in the health care sector.
Confirms:Sector revenue growth falls below its median rate for two consecutive months.
Disproves:Sector revenue growth stays stable or rises above median rates.
Why it matters: The plan is key to reversing recent losses. Success would signal a turnaround in performance.
Confirms:Management says sales growth and profits will improve in the next quarters.
Disproves:Continued net losses and stagnant sales growth in subsequent quarters.
Why it matters: Growth in cash flow shows the company is improving how it operates.
Confirms:Cash from operations increases to above $50M in Q2.
Disproves:Cash from operations drops below $40M in Q2. This shows a setback in cash flow.
Why it matters: Sales growth is key to showing progress in the Return-to-Growth Action Plan. Meeting this target would signal positive momentum.
Confirms:Q2 2026 net sales reported at or above $880 million.
Disproves:Q2 2026 net sales reported below $880 million.
Why it matters: The company is behind on cost management. Progress could improve financial health.
Confirms:Management says the cost management score is above 50%.
Disproves:Cost management score is still below 30%.
Why it matters: The new capital allocation strategy aims to improve liquidity and reduce debt. Its success is crucial for financial health.
Confirms one read:The company reports a decrease in debt by at least $50 million within the next two quarters.
Confirms the other:Debt levels remain unchanged or increase despite the new strategy.
Why it matters: Improving cash flow from operations is key for growth. Weak cash flow raises concerns.
Confirms:Cash flow from operations is much better, showing a good trend.
Disproves:Cash flow from operations declines or remains stagnant.
Why it matters: John Fortson has experience that can help improve finances and strategy. His leadership is important for growth.
Confirms:Fortson starts a new financial plan. It improves cash flow and lowers debt in six months.
Disproves:There is no clear improvement in finances. Losses continue after six months.
Why it matters: The new CFO's strategies could enhance financial discipline and growth. His effectiveness will be crucial for the company's turnaround.
Confirms one read:Q3 2026 showed good financial results and better margins.
Confirms the other:Q3 2026 showed continued losses or lower margins.
Why it matters: Growth in this area is important for overall sales recovery. It shows demand for new dental products.
Confirms:Connected Technology Solutions net sales grow by more than 5% year over year in Q2 2026.
Disproves:Connected Technology Solutions net sales drop or grow less than 1% each year.
Why it matters: The plan aims to make finances stronger. Good execution could help shareholders.
Confirms:Management will report on reducing debt or buying back shares soon.
Disproves:Debt levels remain high. No news on share buybacks.
Why it matters: The new CFO has experience. This could lead to better money management.
Confirms:Look for positive changes in finances or new plans from the new CFO.
Disproves:There are no clear signs of better financial results. The company is still losing money.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
